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Abstract
The role of iron metabolism in Alzheimer's disease (AD) is well documented. Regulation of the
proteins that maintain cellular iron metabolism is mediated by two cytoplasmic RNA-binding
proteins, the Iron Regulatory Proteins (IRP1 and IRP2), that function through
post-transcriptional interactions with RNA stem loop structures called iron-responsive
elements. As the primary mediator of iron homeostasis in neuronal cells, IRP2 is a strong
candidate for polymorphisms that could impact AD pathogenesis. Thus, we performed a pilot
study to assess polymorphisms in the gene encoding IRP2 (IREB2) on clinically
well-characterized, post-mortem samples (50 AD and 50 controls). DNA sequence analysis of
the IREB2 gene region revealed 14 polymorphisms. Two (rs2656070 and rs13180) showed
statistically significant skewing of allelic and genotypic distributions between AD patients and
controls. In silico analyses revealed that rs2656070 lies within a probable promoter and
disrupts the binding sites of at least two known transcription factors. Though silent and likely
not functionally relevant, rs13180 is in complete LD with rs2656070 (D' > 0.999), creating an
IREB2-haplotype that is significantly associated with AD. Confirmation of this association in a
larger cohort of cases and controls would further support the role of iron regulation in the
pathogenesis of this catastrophic and increasingly common neurodegenerative disorder.
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haplotype that is significantly associated with AD. Confirmation of this association in a larger cohort
of cases and controls would further support the role of iron regulation in the pathogenesis of this
catastrophic and increasingly common neurodegenerative disorder.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of disabling cognitive impairment in older
persons. According to one estimate, this disorder afflicts about 10% of everyone over the age
of 65 and almost half of everyone over the age of 85 [12]. As people live longer, the number
of afflicted individuals is projected to multiply. Clinically, AD is characterized by a gradual
but progressive impairment in memory and other cognitive domains. Neuropathologically, the
disorder is characterized by neuritic plaques, neurofibrillary tangles, other histopathological
features, and a loss of synapses and neurons [27]. Although it has been demonstrated that iron
accumulates in brain regions which are histopathologically affected by AD [29], it remains
unclear whether this accumulation is a cause or consequence of these histopathological
features.
Although iron is essential to cellular function, dysregulation of iron metabolism can be toxic
to cells. The regulation of the proteins that maintain iron homeostasis is mediated by a pair of
cytoplasmic RNA-binding proteins known as iron regulatory proteins (IRP1 and IRP2) [25].
These proteins function through post-transcriptional interactions with RNA stem loop
structures called iron-responsive elements (IREs) [13]. Abnormal accumulation of iron in the
brain has been implicated in a variety of neurodegenerative diseases, most notably AD [9].
The genetics of AD remain complex and obscure despite intensive research. Early onset
familial forms of AD appear to be related to mutations in three genes with high penetrance,
the β-amyloid precursor protein (AβPP) gene on chromosome 21 [6], the presenilin 1 (PSEN1)
on chromosome 14 [17,28], and the presenilin 2 (PSEN2) gene on chromosome 1 [17,28], all
resulting in increased amyloid beta (Aβ) production and subsequent neurodegeneration.
However, extensive research has demonstrated that less than 5% of all cases of AD can be
traced to these genetic factors. On the contrary, the majority of AD cases are sporadic, being
associated with late onset and complex genetic etiology. The greatest genetic risk factor
associated with this sporadic form of AD is the apolipoprotein E (APOE) ɛ4 allele on
chromosome 19 [11], however, at least 30 additional candidate genes coding for proteins and
processes considered critical for disease pathogenesis (oxidative stress, apoptosis,
inflammation, increased expression of Aβ, etc.) have been identified, though not consistently
confirmed [8].
Several lines of evidence link dysfunctional iron regulation to the known AD-associated
genetic factors including the ability of iron to regulate translation of the AβPP transcript
through its association with a novel IRE motif in the 5′ upstream region of the AβPP transcript
[24] as well as post-translationally modulate the α-secretase cleavage of AβPP itself [5].
Though the precise makeup of α-secretase has yet to be determined, γ-Secretase-mediated
cleavage of AβPP has been shown to be mediated by the presenilin genes [14]. The APOE
gene has been linked to regulation of cholesterol [15], which has been implicated in promoting
iron-dependent oxidative damage in neurodegeneration [20] and iron has been shown to
increase Aβ aggregation in an APOE isoform-dependent manner [18]. Another iron-related
susceptibility factor that appears to be correlated with AD pathogenesis, and exacerbated in
APOE4 carriers, is the coexpression of the C2 allele of transferrin (TF) gene with the C282Y
allele of the hemachromatosis (HFE) gene [23]. An additional line of evidence demonstrating
the role of iron in AD pathogenesis is the fact that iron chelators significantly enhance the
solubilization of Aβ deposits from postmortem AD brain samples [7]. In fact, the metal chelator
Clioquinol has been demonstrated to slow the clinical progression of AD in humans [22].
Thus, iron dysregulation is viewed as an increasingly important factor in the etiology of AD
and as the primary mediator of iron homeostasis in neuronal cells, IRP2 is a strong potential
candidate for polymorphisms that could play a role in AD. The gene encoding IRP2 (IREB2)
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is located on chromosome 15q25.1 and lies 12.5 Mbp and 23.5 Mbp from previously identified
AD-associated linkage peaks at 15q22 [26] and 15q26 [4], respectively. Ablation of the
IREB2 gene results in neurodegenerative disease in mice via a mechanism of iron dysregulation
[16]. Lastly, IRP2 displays a significantly different distribution between normal and AD-
affected brains and has been co-localized with redox-active iron to histopathological features
of AD including neurofibrillary tangles, senile plaques, and neuropil threads [29].
In order to determine whether or not polymorphisms in the IREB2 gene are associated with
and potentially pathogenic in AD, we performed a pilot study to screen the entire IREB2 gene
in 100 clinically well-characterized, post-mortem brain samples (50 AD patients and 50
unaffected controls) for sequence polymorphisms that are significantly associated with AD.
We report here the identification of a statistically significant association between an IREB2
haplotype and the AD phenotype.
MATERIALS AND METHODS
Population samples
Fresh frozen brain tissue specimens (~500 mg) from the occipital lobe of 100 brain donors
were obtained from the Human Brain and Spinal Fluid Resource Center (Los Angeles, CA).
The donors included 50 persons who satisfied the most recent CERAD criteria for the
neuropathological diagnosis of AD [1,19], including presence of both neuritic plaques and
neurofibrillary tangles in the neocortex (i.e. frequent neuritic plaque score according to
CERAD) and 50 persons who did not satisfy these criteria (i.e. neuropathological examination
confirmed the absence to pathological changes diagnostic for AD). The AD cases were 83 ±
7.0 years of age at the time of death and included 31 females and 19 males. The non-AD controls
were 58 ± 20.9 years of age at the time of death and included 15 females and 35 males. The
non-AD controls showed no evidence of histopathological features associated with AD or
dementia (according to their last antemortem assessment). The sample population was
predominantly Caucasian (86%), but included individuals of African (10%), Latino (2%),
Asian (1%), and Native American (1%) descent (see Table 1 for a breakdown of demographic
characteristics).
Isolation, amplification, and sequencing of DNA
Genomic DNA was extracted from the fresh frozen brain specimens using the Puregene DNA
isolation kit (Gentra Systems, Inc., Minneapolis, MN) according to manufacturer’s
specifications. Following isolation of DNA from all 100 of the fresh frozen brain samples, the
DNA was quantitated using the PicoGreen dsDNA quantitation system (Molecular Probes Inc.,
Eugene, OR), and diluted to 10 ng/μL. 50 ng of total genomic DNA was used to amplify each
of the 22 exons and the 2,241 bp of the 5′ upstream region (purported to contain the IREB2
promoter region) of the IREB2 gene using the primers listed in Table 2 and standard PCR
protocols (available upon request). The entire 2,241 bp of the 5′ upstream region was amplified
using the promoter region 1 forward primer (5′ CCTGCCTCTGTCTCACGGTA 3′) and the
promoter region 4 reverse primer (5′ AACTGCCAGACCCAGCTCGGA 3′), whereas the 22
exons were amplified individually (including ~50–100 bp of flanking sequence containing
intron/exon spicing junctions), with the exception of exons 17 and 18 and exons 19 and 20,
which were amplified in tandem due to their close proximity (but still sequencing 5′ and 3′
splice junction sites). All of the primers used in exon amplification contained either the M13
(−21) universal forward tail (5′ TGTAAAACGACGGCCAGT 3′) or the M13 universal reverse
tail (5′ CAGGAAACAGCTATGACC 3′). PCR products were visualized by agarose gel
electrophoresis.
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Amplified PCR templates were purified with Montage Multiscreen PCRμ96 filter plates
(Millipore Inc., Billerica, MA) according to the manufacturer’s specifications and resuspended
in 25 μL molecular biology grade (MBG) water. The purified samples were analyzed by
agarose gel electrophoresis and compared to a known standard to determine the optimum
concentration for DNA sequence analysis.
For the 22 exons, both strands of each PCR product were sequenced as follows: Sequencing
reactions were performed using 3 μL (approximately 25 ng) of purified PCR product in a 6
μL reaction containing 0.33 μL BigDye Terminator v3.1 premix (Applied Biosystems, Foster
City, CA), 3.2 pmol of either M13 forward or M13 reverse primer, and 1.03 μL 5X BigDye
sequencing buffer. Cycle-sequencing was performed for 35 cycles following the manufacturers
recommendations on GeneAmp 9700 PCR machines (Applied Biosystems, Foster City, CA).
Sequencing reactions were purified using CleanSEQ® (Agencourt Biosciences Corp., Beverly,
MA) to remove unincorporated dye-terminators, and analyzed on 3730xl DNA analyzers
(Applied Biosystems, Foster City, CA). The 5′ upstream region was sequenced in four segments
using the purified 2,241 bp amplicon as the template and 4 sets of internal sequencing primers
as shown in Table 2. Otherwise, the protocol was identical to that above.
Sequence and statistical analyses
DNA sequences were checked for accuracy by sequencing both strands in opposite directions
and comparing the sequence of each strand to one another. Individual forward and reverse
sequence traces were aligned to each other in the Sequencher program (Gene Codes Corp.,
Ann Arbor, MI) and ambiguities were resolved by visual observation of peak heights.
Polymorphisms in exons were identified by comparison to the updated reference sequence for
the IREB2 cDNA in the GenBank database (NCBI accession NM_004136), whereas
polymorphisms in the 5′ upstream region were identified by comparison to an available
genomic reference sequence for IREB2 in the Celera database (Celera accession hCG38938).
The novelty of the observed polymorphisms was assessed by screening the available SNP
database (http://genome.ucsc.edu/) for previously demonstrated occurrences of the SNP.
The distribution of sequence polymorphisms between affected and unaffected controls was
assessed and statistically evaluated via the chi-square test. Those found to be statistically
significant were additionally tested using the Fisher’s Exact statistical test as well as the
Bonferonni correction for multiple testing. Analysis of linkage disequilibrium, haplotype
reconstruction, and haplotype trend regression analysis was done with PowerMarker v. 3.22
(http://statgen.ncsu.edu/powermarker/). Polymorphisms demonstrating statistically significant
distributions between AD patients and unaffected controls were subject to further analyses of
functional relevance via a variety of in silico tests.
In silico analyses
In order to assess potential functional relevance of SNPs located in the 5′ upstream region of
the IREB2 gene, in silico promoter analysis was performed on the 10,000 bp of 5′ upstream
region flanking sequence using the NIH promoter scanning software package PROSCAN v.
1.7 (http://bimas.cit.nih.gov/molbio/proscan/) [21]. The 500 bp sequence containing the
putative promoter region was subsequently used to search the TRANSFAC 6.0 database of
transcription factor binding sites (http://www.gene-regulation.com/pub/
databases.html#transfac) via the Ali Baba v. 2.1 software package. SNP rs13180 was tested
for its ability to act as an exonic splice enhancer using the ESE Finder (http://rulai.cshl.edu/
tools/ESE/).
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RESULTS
Sequence analysis of the entire IREB2 gene (including intron/exon splice sites) as well as 2,241
bp of the 5′ upstream region identified 14 polymorphisms (Table 3). Five of the polymorphisms
were located in coding regions, one was in an intronic region between exons 19 and 20, and
the remaining eight were found in the 5′ upstream region. There were ten transitions and four
transversions. All of the polymorphisms were blasted using blastn [2] against the HG16 build
(NCBI Build 34) of the UCSC Genome Browser (http://genome.ucsc.edu/) SNP track on Oct.
27th, 2004. All numbering is from the initiator methionine ATG (A = 1) based on the IREB2
cDNA sequence (NCBI accession NM_004136) and/or the IREB2 genomic sequence (Celera
accession hCG38938), which are noted as the “reference” sequence. Six of the polymorphisms
have been previously identified and assigned refseq numbers (bp –2072 A/G = rs2102264; bp
–763 C/G = rs2568484; bp –428 G/A = rs2656070; bp –89 T/C = rs954144; X19+12 C/A =
rs4887060; and bp 2616 C/T = rs13180). The other eight polymorphisms have not previously
been described. Three of the polymorphisms located within exons changed an amino acid,
whereas the other two were silent. Each of the 14 identified polymorphisms was tested
individually for differences in genotype distribution between groups (AD vs. unaffected
control). Using the chi-square test, two of the polymorphisms (rs2656070 and rs13180)
demonstrated a statistically significant genotype distribution between AD patients and
unaffected controls at the p < 0.05 and p < 0.001 levels, respectively, with no correction for
type 1 errors (Table 3). These two SNPs were further tested using the Fisher’s Exact test and
found to demonstrate statistical significance at the p < 0.035 and p < 0.001 levels, respectively,
with no correction for Type 1 errors. Applying the Bonferonni correction for multiple testing
(alpha’ = 0.05/14 = 0.0036), rs2656070 fails to maintain statistical significance (p > 0.004),
but rs13180 retains its statistical significance (p < 0.001). The precise genotypic distribution
of these two significant SNPs is displayed in Table 4.
The bp –428 G/A polymorphism in the 5′ upstream region of the IREB2 gene (rs2656070) has
been observed previously, but no allele frequency information is currently available. In order
to assess whether or not this polymorphism has any functional relevance, an in silico promoter
analysis was performed whereby 10,000 bp of 5′ upstream region sequence from the IREB2
gene was analyzed using the NIH promoter scanning software package PROSCAN v. 1.7
(http://bimas.cit.nih.gov/molbio/proscan/) [21]. The highest scoring predicted promoter region
(promoter score: 83.68) was located between bp 9,502 and p9,752 in the forward strand, which
corresponds to between –248 and –498 bp upstream of the transcriptional start site (bp –428
G/A lies within this region). A 500 bp sequence containing this putative promoter region was
subsequently used to search the TRANSFAC 6.0 database of transcription factor binding sites
(http://www.gene-regulation.com/pub/databases.html#transfac) via the Ali Baba v. 2.1
software package. The results of this analyses showed that rs2656070 disrupts the recognition
sequence of at least two known transcription factors (AP-1 and Sp1). Thus, in silico analyses
suggest that rs2656070 lies within the most highly predicted promoter sequence in the
IREB2 gene and disrupts the recognition sequence of at least two known transcription factors.
The bp 2616 C/T polymorphism is silent, maintaining an alanine at amino acid position 872.
As mentioned, this polymorphism has also been described previously (rs13180) and the
frequency of the C/T allele is 0.564 and 0.436, respectively (http://www.ncbi.nlm.nih.gov/
SNP/). This SNP was tested for the ability to act as an exonic splice enhancer (ESE) using ESE
finder (http://rulai.cshl.edu/tools/ESE/). This polymorphism actually demonstrates the ability
to act as an ESE, but the base change from C to T doesn’t appear to significantly affect this
potential.
Due to the high level of statistical significance for this polymorphism observed between AD
patients and unaffected controls, we predicted that it may be linked to another polymorphism
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that is the true functional variant. To identify the extent of LD from the significantly associated
SNPs, we calculated pairwise linkage disequilibrium statistics for all observed polymorphisms
using the PowerMarker v. 3.22 program (http://statgen.ncsu.edu/powermarker). The two
statistically significant SNPs (rs2656070 and rs13180) were found to be in almost complete
linkage disequilibrium (D′ > 0.999) creating an IREB2-related haplotype. Haplotype trend
regression analysis revealed that this haplotype is significantly associated with AD risk ( p <
0.001). Because the SNPs are interrelated, we used forward and backward logistic regression
analysis with both SNPs as independent variables and using the additive model. Under this
model, only rs13180 remained significant (p < 0.001, OR 4.4, chi-square = 10.9). No
significance remained for rs2656070 (p = 0.9).
DISCUSSION
In this preliminary study of 50 neuropathologically well-characterized AD cases and 50
unaffected controls, AD was significantly associated with an IREB2-related haplotype with a
potentially functionally relevant SNP in the 5′ upstream region (p < 0.001). DNA sequence
analysis of all 22 exons of the IREB2 gene (including splice junction sites) as well as 2,241 bp
of the 5′ upstream region containing the promoter revealed the presence of 14 polymorphisms.
Two of these, a G/A transition at bp –428 in the 5′ upstream region (rs2656070) and a silent
C/T transition at bp 2616 in exon 21 of the IREB2 coding region (rs13180), showed statistically
significant distributions between AD patients and unaffected controls via chi-square at the p
< 0.05 and p < 0.001 levels (p < 0.035 and p < 0.001 via Fisher’s Exact test), respectively.
In silico analyses revealed rs2656070 lies within a probable promoter and disrupts the binding
sites of at least two known transcription factors (AP-1 and Sp1). Although c-MYC has been
suggested to play a role in the regulation of IREB2 transcription [31], a clear understanding of
IREB2 transcriptional regulation remains elusive. Thus, the finding that rs2656070 is located
in a probable promoter region and disrupts the binding sites of these two different transcription
factors is intriguing and warrants further investigation. Though silent and likely not
functionally relevant despite a potential role as an exonic splice enhancer, rs13180 shares
significant levels of linkage disequilibrium with rs2656070 (D′ > 0.999), creating an IREB2-
related haplotype that is significantly associated with AD (p < 0.001). These results suggest
that there have been minimal amounts of historic recombination in the IREB2 genomic region
and that there is a strong correlation of alleles at these two sites. Interestingly, rs13180 is located
at the very end of a haplotype block in Caucasians (http://www.celera.com). Also interestingly,
this haplotype block ends with rs13180 only in Caucasians, whereas Chinese and African
populations display an extended block that includes the nearby locus LOC123688. It is also
possible that rs13180 is also in LD with an as yet unidentified SNP and it is known that a group
of nicotinic acetylcholine receptor subunits known to be associated with AD [10,30] are located
about 200 kb 3′ upstream of rs13180 [3].
Although the finding of the statistically significant polymorphisms with in silico data
suggesting a possible functional role for the SNP is intriguing, findings from our study must
be considered exploratory, given the small number of subjects and potential for Type 1 errors.
Type I errors are essentially “false positives” that occur when multiple tests are performed,
whereby statistical associations are seen purely by chance alone. Using a confidence interval
of 95% (p < 0.05), the chances of obtaining a statistically significant association by chance
alone is 1 in 20 (5%). That chance increases to 7% in our sample due to the smaller number of
tests (i.e. 14 SNPs/tests). To guard against Type 1 errors caused by multiple testing, we applied
the Bonferroni correction (dividing the confidence interval by the number of tests) to the two
SNPs shown to be significant and found that only rs13180 retains statistical significance (p <
0.001).
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It should also be noted that the cases and controls show some disparity in mean age. In order
to determine whether or not age had any effect on our genotypic and allelic distributions, we
reran the logistic regression analysis, a regression-based analysis testing the association of
haplotype and trait (quantitative or qualitative) with one regression coefficient per haplotype
permitting the inclusion of covariates and moderator variables (e.g. age, gender, etc), adjusting
for age and gender and found that the haplotype remains statistically significant (p = 0.043).
To further rule out the possibility that our association is due to solely to age, we removed all
young individuals (< 65 yrs. old) from the control cohort and re-analyzed the data (n = 21).
Using this model and the Fisher’s Exact test, we find that the significance of the two SNPs is
maintained, albeit at lower levels (p < 0.033 for rs2656070 and p < 0.034 for rs13180), due to
reduced power.
Because the two significant SNPs are interrelated (D′ = 0.99), we ran forward and backward
logistic regression analysis with both SNPs as independent variables using the additive model.
This analysis revealed that only rs13180 remained significant at the p < 0.001 level (OR 4.4,
chi-square = 10.9) and no significance remained for rs2656070 (p = 0.9), which is expected
as rs13180 seems to be driving the association. However, given that LD does not always decay
in a linear mode, the analysis of promoter SNPs (i.e. rs2656070) could still be promising. If
non-Caucasians are excluded, the picture is the same at the p < 0.004 level due to slightly
reduced power. Additionally, in order to further exclude the possibility that our distributions
were skewed by ethnicity, we eliminated the 10 Africans, 2 Latinos, 1 Asian, and 1 Native
American present in the sample and re-analyzed the data. The statistical significance of the
distributions of these two SNPs either increased or remained unchanged with the exclusion of
samples that could possibly impose any racial bias.
In conclusion, we find by application of multiple statistical models, that the association of the
driving SNP (rs13180) as well as the haplotype to the AD phenotype remains statistically
significant despite any potential age and/or racial bias. Though extremely encouraging, these
findings need to be confirmed in an independent sample and their functional significance
clarified in additional validation experiments. In order to assess the frequency of these
polymorphisms/haplotype more precisely, we propose to genotype these SNPs in larger
samples of cases and controls. Once haplotype frequencies are established, we propose to
determine the functional relevance of this haplotype by cloning haplotype-specific promoter
fragments into the pGL3-Basic vector and assaying promoter activity via a dual-luciferase
system. If the association between this haplotype and AD can be confirmed in a large, ethnically
diverse population, it would provide further support for the role of iron in the pathogenesis of
AD and provide additional information about the heritable risk factors associated with this
catastrophic and increasingly common neurodegenerative disorder.
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